Clinical Trials Logo
  1. Home
  2. Amyloid Cardiomyopathy
  3. NCT06328075

Artificial Intelligence to Assist the Echocardiographic Identification of Transthyretin Cardiac Amyloidosis — AI-ATTR-ECHO  

Amyloid Cardiomyopathy Clinical Trial

Official title:
Artificial Intelligence to Assist the Echocardiographic Identification of Transthyretin Cardiac Amyloidosis

Clinical Trial Summary

The goal of this study is to develop an algorithm using artificial intelligence (AI) to assist identification of potential ATTR-CM cases using routine transthoracic echocardiography. The main questions it aims to answer are: - is the algorithm able to diagnose ATTR-CM - is the algorithm able to diagnose different types of ATTR-CM (ATTRv, ATTRwt) This is a non interventional study. Participant' echocardiographies will be, after deidentification, used to train, valid and test the algorithm.

Clinical Trial Description

Transthyretin (TTR) amyloidosis is a serious systemic disease affecting multiple target organs including the peripheral nervous system, heart, and kidney. In the absence of treatment, the median survival for symptomatic forms with cardiac involvement is 3 to 4 years. In recent years, new treatments have proven their effectiveness in transthyretin amyloidosis, making it possible to slow the progression of neuropathy and cardiac damage. These treatments seem particularly effective when they are initiated at an early stage of the disease. It is therefore necessary to establish the diagnosis as early as possible in order to benefit the most from the treatment. However, during the clinical examination, the electrocardiogram or the routine echocardiography, the signs evoking cardiac amyloidosis are not specific. The initial diagnosis is therefore often difficult, missed or delayed and the median time between the first symptoms and the initiation of treatment is approximately 3 years. It is therefore the initial phase of diagnosis that must be improved in a sufficiently sensitive and specific manner to detect potential cases early while avoiding unnecessary examinations in the event of a low probability. The objective of the study is to develop and validate a tool to assist the screening of cardiac transthyretin amyloidosis, from standard echocardiography, without the need for active participation of the cardiologist in the diagnostic process. This diagnostic contribution will allow the cardiologist to evoke the diagnosis of cardiac amyloidosis and to consider additional explorations. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06328075
Study type Observational
Source Bichat Hospital
Contact Vincent Algalarrondo, MD, PhD
Phone +33140257785
Email vincent.algalarrondo@aphp.fr
Status Recruiting
Phase
Start date January 1, 2022
Completion date January 1, 2026
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05896904 - Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction N/A
Active, not recruiting NCT06257485 - Bronx Transthyretin Amyloid Cardiomyopathy Database
Recruiting NCT06086353 - A Study to Learn About Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in India
Active, not recruiting NCT06321523 - A Study to Learn About the Study Medicine Called Tafamidis 61mg in People Diagnosed With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Completed NCT05233163 - SGLT2 Inhibitors in Transthyretin Amyloid Cardiomyopathy Phase 4
Not yet recruiting NCT06101108 - Early Diagnosis of Age-Linked CArdiac TransThyRetin Amyloidosis by Selective Screening in Spinal Stenosis Surgery
Completed NCT04814186 - A Study to Assess the Safety and Efficacy Of Tafamidis In Chinese Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Phase 4
Recruiting NCT04899180 - Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis Early Phase 1
Recruiting NCT05259072 - carDIo-ttranSSfOrm nucLEar Imaging Study Phase 3
Recruiting NCT06183931 - Study of ALXN2220 Versus Placebo in Adults With ATTR-CM Phase 3
Recruiting NCT06291805 - Phenotyping and Characterization of wtATTR-CM (TRACE 1)
Terminated NCT04424914 - Global Prevalence of ATTR-CM in Participants With HFpEF N/A
Recruiting NCT06194825 - EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy Phase 3
Recruiting NCT06372301 - Dobutamine Stress Echocardiography in LF/LG Aortic Stenosis and Wild-type Transthyretin Amyloid Cardiomyopathy N/A